Texas Doctor's DEA License Yanked Over Suspension Drama
Published Date: 3/27/2025
Notice
Summary
Dr. Willard J. Davis from Texas lost his DEA registration because his medical license was suspended, meaning he can’t legally handle controlled substances anymore. The DEA reviewed the case, agreed with the suspension, and officially revoked his registration. This means Dr. Davis must stop all controlled substance activities immediately, affecting his medical practice and any related income.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Davis
The DEA revoked Willard J. Davis, D.O.'s Certificate of Registration No. BD9134254, so he must stop all controlled-substance activities immediately. The revocation follows the suspension of his Texas medical license on May 16, 2024, and the Order is effective April 28, 2025, which will affect his medical practice and any related income.
Future DEA Applications Denied in Texas
The DEA also denied any pending applications by Willard J. Davis, D.O., to renew or modify his registration and denied any other pending application for additional registration in Texas. That denial accompanies the revocation and is effective April 28, 2025, restricting his ability to regain DEA authorization in Texas.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-05165 — Harvey Leslie, M.D.; Decision and Order
Dr. Harvey Leslie from Georgia lost his medical license earlier this year, so the DEA is officially taking away his permission to handle controlled substances. Since he didn’t ask for a hearing, the DEA’s decision is final, meaning he can no longer prescribe or manage these drugs. This change is immediate and affects Dr. Leslie’s ability to work with controlled medicines, with no money or appeals left on the table.
Next: 2025-05167 — Notice of Intent To Decommission Flight Service Remote Communications Outlets (RCOs)
The FAA plans to shut down some Flight Service radio stations that pilots use to get advice while flying across the lower 48 states (but not Alaska). This change means pilots will rely on other ways to get info, and the FAA wants your thoughts before making it official. No big costs or dates are set yet, but the switch could happen soon!